M
Mark Hennon
Researcher at Roswell Park Cancer Institute
Publications - 57
Citations - 3030
Mark Hennon is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Pneumonectomy & Lung cancer. The author has an hindex of 15, co-authored 51 publications receiving 2324 citations. Previous affiliations of Mark Hennon include University at Buffalo & State University of New York System.
Papers
More filters
Journal ArticleDOI
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Michael C. Dobelbower,Robert C. Doebele,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Leah J. Leisch,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +34 more
TL;DR: This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastasis disease.
Journal ArticleDOI
Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines
David S. Ettinger,Douglas E. Wood,Charu Aggarwal,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Ankit Bharat,Debora S. Bruno,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Michael C. Dobelbower,Scott N. Gettinger,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Jules Lin,Billy W. Loo,Renato Martins,Gregory A. Otterson,Sandip Pravin Patel,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +35 more
TL;DR: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) as discussed by the authors address all aspects of management for NSCLC, focusing on recent updates in immunotherapy.
Journal ArticleDOI
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
David S. Ettinger,Dara L. Aisner,Douglas E. Wood,Wallace Akerley,Jessica Bauman,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,Michael C. Dobelbower,Ramaswamy Govindan,Matthew A. Gubens,Mark Hennon,Leora Horn,Rudy P. Lackner,Michael Lanuti,Ticiana A. Leal,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato G. Martins,Gregory A. Otterson,Sandip Pravin Patel,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +32 more
TL;DR: The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC and for the 2018 update, a new section on biomarkers was added.
Journal ArticleDOI
NCCN Guidelines ® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
David S. Ettinger,Douglas E. Wood,Wallace Akerley,Lyudmila Bazhenova,Hossein Borghaei,D.R. Camidge,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Thomas J. Dilling,M. Chris Dobelbower,Ramaswamy Govindan,Mark Hennon,Leora Horn,Thierry Jahan,Ritsuko Komaki,Rudy P. Lackner,Michael Lanuti,Rogerio Lilenbaum,Jules Lin,Billy W. Loo,Renato G. Martins,Gregory A. Otterson,Jyoti D. Patel,Katherine M.W. Pisters,Karen L. Reckamp,Gregory J. Riely,Steven E. Schild,Theresa A. Shapiro,Neelesh Sharma,James P. Stevenson,Scott J. Swanson,Kurt Tauer,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +35 more
TL;DR: New immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC are discussed, based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
Journal ArticleDOI
Safety of Thoracoscopic Lobectomy in Locally Advanced Lung Cancer
Mark Hennon,Rohit K. Sahai,Sai Yendamuri,Sai Yendamuri,Wei Tan,Todd L. Demmy,Todd L. Demmy,Chukwumere Nwogu,Chukwumere Nwogu +8 more
TL;DR: Thoracoscopic lobectomy for advanced-stage NSCLC can be performed safely, with results equivalent to open techniques, and lower morbidity with resections performed by video-assisted thoracoscopic surgery will be expected, similar to that observed with early-stage disease.